Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Q3 FY25 revenue up 24% to Rs 3,230 crore
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
EBITDA margins expand to 31.3%
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Subscribe To Our Newsletter & Stay Updated
